首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1897327

重組疫苗市場規模、佔有率及成長分析（按類型、疾病、最終用戶、通路及地區分類）－2026-2033年產業預測

Recombinant Vaccines Market Size, Share, and Growth Analysis, By Type, By Disease, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，重組疫苗市場規模將達到 112 億美元，到 2025 年將達到 124.7 億美元，到 2033 年將達到 295.8 億美元，在預測期（2026-2033 年）內，複合年成長率為 11.4%。

重組疫苗代表著疫苗接種策略的模式轉移，它摒棄了依賴病原體暴露的傳統方法。這些疫苗利用基因工程、基因組學和重組DNA技術的進步，在受控的實驗室環境中設計，並採用基因篩檢來降低與感染疾病相關的風險。這種創新方法提高了疫苗的有效性和安全性，代表著疫苗研發領域的重大進步。透過實現更精準、更個人化的免疫接種過程，重組疫苗能夠有效應對各種健康挑戰。這項發展不僅加強了公共衛生應對能力，也凸顯了疫苗技術持續進步的巨大潛力，使其成為醫療保健市場值得關注的領域。

重組疫苗市場促進因素

重組疫苗市場的成長主要得益於重組技術的廣泛應用，該技術顯著提高了疫苗的安全性和有效性。這項技術能夠實現疫苗的快速大規模生產，緩解供不應求，確保供應穩定。此外，重組疫苗不含感染性病毒顆粒，因此對免疫力的人更為安全。這些卓越的疫苗特性促使生產者致力於研發對抗病毒性疾病的新產品。為此，他們正積極利用先進的DNA技術、基因組學和其他前沿生物技術方法，開發更有效、更安全的疫苗。

重組疫苗市場限制因素

重組疫苗市場面臨許多挑戰，阻礙其成長，其中高成本是一大障礙。儘管世界衛生組織（世衛組織）等機構正積極努力，透過在全球分發數百萬劑疫苗來擴大免疫接種範圍，但這些疫苗的高昂價格仍然是許多地區面臨的一大難題。儘管各方努力改善疫苗的可及性，並覆蓋服務不足的社區，但由於價格過高，許多地區仍然難以獲得疫苗。此經濟因素持續構成重大限制，影響各社區疫苗接種計畫的整體有效性。

重組疫苗市場趨勢

由於全球感染疾病率不斷上升，以及對有效疫苗接種策略的迫切需求，重組疫苗市場正經歷顯著成長。某些人群，特別是老年人和兒童，日益成長的脆弱性進一步推動了對這些先進疫苗的需求。聯合國兒童基金會和泛美衛生組織等機構在促進疫苗快速分發、滿足緊急醫療需求以及增強社區對各種病原體的抵抗力方面發揮關鍵作用。這些國際組織的堅定承諾不僅遏制了疾病傳播，也促進了重組疫苗領域的創新和發展，使其成為現代醫療保健策略的重要組成部分。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Pfizer Inc.（United States）
GlaxoSmithKline plc（GSK）（United Kingdom）
Merck & Co., Inc.（United States）
Moderna, Inc.（United States）
Novavax, Inc.（United States）
Johnson & Johnson（United States）
AstraZeneca plc（United Kingdom）
Bavarian Nordic A/S（Denmark）
BioNTech SE（Germany）
Vaxart, Inc.（United States）
Transgene SA（France）
GeoVax Labs, Inc.（United States）
Vaxcyte, Inc.（United States）
Green Cross Corporation（GC Biopharma）（South Korea）
Bharat Biotech International Limited（India）
Shantha Biotechnics Limited（India）
Valneva SE（France）
Inovio Pharmaceuticals, Inc.（United States）
Sinovac Biotech Ltd.（China）

結論與建議

簡介目錄

Product Code: SQMIG35A2787

Recombinant Vaccines Market size was valued at USD 11.2 Billion in 2024 and is poised to grow from USD 12.47 Billion in 2025 to USD 29.58 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).

Recombinant vaccines represent a paradigm shift in immunization strategies, moving away from conventional methods that relied on pathogen exposure. Leveraging advancements in genetic engineering, genomics, and recombinant DNA technologies, these vaccines are designed in controlled laboratory settings, employing genetic screening to mitigate risks associated with infectious diseases. This innovative approach enhances both the efficacy and safety of vaccines, marking a substantial improvement in vaccine development. By allowing for a more precise and tailored immunization process, recombinant vaccines are positioned to address various health challenges effectively. This evolution not only strengthens public health responses but also highlights the potential for ongoing advancements in vaccine technology, making it an exciting area in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Vaccines Market Segments Analysis

Global Recombinant Vaccines Market is segmented by Type, Disease, End User, Distribution Channel and region. Based on Type, the market is segmented into Subunit recombinant vaccines, Attenuated recombinant vaccines and Vector recombinant vaccines. Based on Disease, the market is segmented into Pneumococcal Disease, Cancer, Hepatitis B, Influenza, DPT and Others. Based on End User, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Retail Pharmacies and Government Suppliers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Vaccines Market

The growth of the recombinant vaccines market is significantly driven by the widespread adoption of recombinant technology, which greatly improves the safety and effectiveness of vaccines for patients. This technology allows for the rapid and large-scale production of vaccines, reducing supply shortages and ensuring availability. Additionally, recombinant vaccines are free from infectious viral particles, making them safer for those with weakened immune systems. The positive attributes of these vaccines have motivated manufacturers to concentrate on innovating new products aimed at combating viral diseases. This focus involves utilizing advanced DNA technology, genomics, and other state-of-the-art biotechnological approaches to develop vaccines that are not only more effective but also safer overall.

Restraints in the Recombinant Vaccines Market

The Recombinant Vaccines market faces several challenges that hinder its growth, with the high cost per dose being a primary obstacle. Although global health organizations are actively working to enhance vaccination efforts by distributing millions of doses worldwide, the expensive nature of these vaccines remains a significant barrier for various populations. Even as initiatives aim to improve access and reach underserved areas, many regions still experience difficulties in obtaining vaccines due to their prohibitive costs. This economic factor continues to be a major limitation, impacting the overall effectiveness of vaccination programs across different communities.

Market Trends of the Recombinant Vaccines Market

The Recombinant Vaccines market is experiencing significant growth driven by the rising global incidence of infectious diseases and the urgent need for effective immunization strategies. The heightened vulnerability of specific demographics, particularly the elderly and pediatric populations, amplifies the demand for these advanced vaccines. Organizations like UNICEF and PAHO are pivotal in facilitating the swift distribution of vaccine doses, addressing emergency healthcare needs, and enhancing community resilience against various pathogens. This robust engagement from international bodies not only mitigates disease transmission but also fosters innovation and development within the recombinant vaccine sector, positioning it as a critical component of modern healthcare strategies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Recombinant Vaccines Market Size by Type & CAGR (2026-2033)

Market Overview
Subunit recombinant vaccines
Attenuated recombinant vaccines
Vector recombinant vaccines

Global Recombinant Vaccines Market Size by Disease & CAGR (2026-2033)

Market Overview
Pneumococcal Disease
Cancer
Hepatitis B
Influenza
DPT
Others

Global Recombinant Vaccines Market Size by End User & CAGR (2026-2033)

Market Overview
Pediatric
Adult
Geriatric

Global Recombinant Vaccines Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital & Retail Pharmacies
Government Suppliers

Global Recombinant Vaccines Market Size & CAGR (2026-2033)

North America (Type, Disease, End User, Distribution Channel)
- US
- Canada
Europe (Type, Disease, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Disease, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Disease, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Disease, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bavarian Nordic A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxart, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GeoVax Labs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxcyte, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation (GC Biopharma) (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bharat Biotech International Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shantha Biotechnics Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valneva SE (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sinovac Biotech Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments